The effects of cannabinoid administration on sleep: A systematic review of human studies

Sleep Medicine Reviews

Volumn 18, Issue 6, 2014, Pages 477-487

  Gates, Peter J ^a   Albertella, Lucy ^a   Copeland, Jan ^a  

^a UNIVERSITY OF NEW SOUTH WALES   (Australia)

Author keywords

Cannabis; Insomnia; Marijuana; Sleep

Indexed keywords

CANNABINOID;

AROUSAL; CANNABIS USE; HUMAN; REVIEW; SLEEP; SLEEP DISORDER; SLEEP TIME; SLOW WAVE SLEEP; SYSTEMATIC REVIEW; CANNABIS ADDICTION; COMPLICATION; DRUG EFFECTS;

CANNABINOIDS; HUMANS; MARIJUANA ABUSE; SLEEP;

EID: 84923217553     PISSN: 10870792     EISSN: 15322955     Source Type: Journal    
DOI: 10.1016/j.smrv.2014.02.005     Document Type: Review

References (71)

1. UNODC World drug report 2013 2013, United Nations Publication, [Sales No. E.13.XI.6].
2. Copeland J., Rooke S., Swift W. Changes in cannabis use among young people: impact on mental health. Curr Opin Psychiatry 2013, 26:325-329.
3. Horwood L.J., Fergusson D.M., Coffey C., Patton G.C., Tait R., Smart D., et al. Cannabis and depression: an integrative data analysis of four Australasian cohorts. Drug Alcohol Depend 2012, 126:369-378.
4. Macleod J., Oakes R., Copello A., Crome I., Egger M., Hickman M., et al. Psychological and social sequelae of cannabis and other illicit drug use by young people: a systematic review of longitudinal, general population studies. Lancet 2004, 363:1579-1588.
5. Tashkin D.P. Effects of marijuana smoking on the lung. Proc Am Thorac Soc 2013, 10:239-247.
6. Roffman R., Stephens R.S., Marlatt G.A. Cannabis dependence: its nature, consequences and treatment 2006, Cambridge University Press, Cambridge.
7. Zuardi A.W., Crippa J.A., Hallak J.E., Moreira F.A., Guimaraes F.S. Cannabidiol, a cannabis sativa constituent, as an antipsychotic drug. Braz J Med Biol Res 2006, 39:421-429.
8. Borgelt L.M., Franson K.L., Nussbaum A.M., Wang G.S. The pharmacologic and clinical effects of medical cannabis. Pharmacotherapy 2013, 33:195-209.
9. Lee C.M., Neighbors C., Woods B.A. Marijuana motives: young adults' reasons for using marijuana. Addict Behav 2007, 32:1384-1394.
10. Green B., Kavanagh D., Young R. Being stoned: a review of self-reported cannabis effects. Drug Alcohol Rev 2003, 22:453-460.
11. Ohayon M.M. Epidemiology of insomnia: what we know and what we still need to learn. Sleep Med Rev 2002, 6:97-111.
12. Zammit G.K., Weiner J., Damato N., Sillup G.P., McMillan C.A. Quality of life in people with insomnia. Sleep 1999, 22:379-385.
13. Benca R.M. Consequences of insomnia and its therapies. JClin Psychiatry 2001, 62:33-38.
14. Schierenbeck T., Riemann D., Berger M., Hornyak M. Effect of illicit recreational drugs upon sleep: cocaine, ecstasy and marijuana. Sleep Med Rev 2008, 12:381-389.
15. Russo E.B., Guya G.W., Robsona P.J. Cannabis, pain, and sleep: lessons from therapeutic clinical trials of sativex, a cannabis-based medicine. Chem Biodivers 2007, 4:1729-1743.
16. Reinarman C., Nunberg H., Lanthier F., Heddleston T. Who are medical marijuana patients? Population characteristics from nine California assessment clinics. JPsychoactive Drugs 2011, 43:128-135.
17. Tringale R., Jensen C. Cannabis and insomnia. Depression 2011, 4:0-68.
18. Schofield D., Tennant C., Nash L., Degenhardt L., Cornish A., Hobbs C., et al. Reasons for cannabis use in psychosis. Aust N Z J Psychiatry 2006, 40:570-574.
19. Glozier N., Martiniuk A., Patton G., Ivers R., Li Q., Hickie I., et al. Short sleep duration in prevalent and persistent psychological distress in young adults: the DRIVE study. Sleep 2010, 33:1139-1145.
20. Freeman D., Brugha T., Meltzer H., Jenkins R., Stahl D., Bebbington P. Persecutory ideation and insomnia: findings from the second British national survey of psychiatric morbidity. JPsychiatr Res 2010, 44:1021-1026.
21. Wong M.M., Brower K.J., Zucker R.A. Childhood sleep problems, early onset of substance use and behavioral problems in adolescence. Sleep Med 2009, 10:787-796.
22. Mednick S.C., Christakis N.A., Fowler J.H. The spread of sleep loss influences drug use in adolescent social networks. PLoS One 2010, 5:e9775.
23. Bolla K.I., Lesage S.R., Gamaldo C.E., Neubauer D.N., Wang N.Y., Funderburk F.R., et al. Polysomnogram changes in marijuana users who report sleep disturbances during prior abstinence. Sleep Med 2010, 11:882-889.
24. Allsop D.J., Norberg M.M., Copeland J., Fu S., Budney A.J. The Cannabis Withdrawal Scale development: patterns and predictors of cannabis withdrawal and distress. Drug Alcohol Depend 2011, 119:123-129.
25. The Cochrane Collaboration's tool for assessing risk of bias. Cochrane handbook for systematic reviews of interventions [Internet] 2011, The Cochrane Collaboration, The Cochrane Collaboration, Available from:. http://www.cochrane-handbook.org.
26. Cochrane effective practice and organisation of care review group: data collection checklist 2009, The Cochrane Collaboration, The Cochrane Collaboration, Available from:. http://epoc.cochrane.org/sites/epoc.cochrane.org/files/uploads/datacollectionchecklist.pdf.
27. Viswanathan M., Ansari M.T., Berkman N.D., Chang S., Hartling L., McPheeters L.M., et al. Assessing the risk of bias of individual studies in systematic reviews of health care interventions. Methods guide for effectiveness and comparative effectiveness reviews 2012, AHRQ, Publication No. 12-EHC047-EF. http://www.ncbi.nlm.nih.gov/books/NBK91433/, (US) AfHRaQ (Ed.).
28. Barratt E.S., Beaver W., White R. The effects of marijuana on human sleep patterns. Biol Psychiatry 1974, 8:47-54.
29. Hosko M.J., Kochar M.S., Wang R.I.H. Effects of orally administered delta 9 tetrahydrocacannabiol in man. Clin Pharmacol Ther 1973, 14:344-352.
30. Karacan I., Fernandez Salas A., Coggins W.J. Sleep electroencephalographic electrooculographic characteristics of chronic marijuana users. I. Ann N Y Acad Sci 1976, 282:348-374.
31. Nicholson A.N., Turner C., Stone B.M., Robson P.J. Effect of delta-9-tetrahydrocannabinol and cannabidiol on nocturnal sleep and early-morning behavior in young adults. JClin Psychopharmacol 2004, 24:305-313.
32. Pranikoff K., Karacan I., Larson E.A., Williams R.L., Thornby J.I., Hursch C.J. Effects of marijuana smoking on the sleep EEG. Preliminary studies. JFMA 1973, 60:28-31.
33. Tassinari C.A., Ambrosetto G., Peraita-Adrado M.R., Gastaut H. The neuropsychiatric syndrome of delta-9 tetrahydrocannabinol and cannabis intoxication in naive subjects: a clinical and polygraphic study during wakefulness and sleep. Marihuana and medicine 1999, 649-664. Humana Press, Inc., Totowa. G.G. Nahas, K.M. Sutin, D.J. Harvey, S. Agurell, N. Pace, R. Cancro (Eds.).
34. Babor T.F., Mendelson J.H., Kuehnle J. Marihuana and human physical activity. Psychopharmacology 1976, 50:11-19.
35. Chait L.D., Perry J.L. Acute and residual effects of alcohol and marijuana, alone and in combination, on mood and performance. Psychopharmacology 1994, 115:340-349.
36. Chait L.D. Subjective and behavioral effects of marijuana the morning after smoking. Psychopharmacology 1990, 100:328-333.
37. Chait L.D., Zacny J.P. Reinforcing and subjective effects of oral delta 9-THC and smoked marijuana in humans. Psychopharmacology 1992, 107:255-262.
38. Cousens K., DiMascio A. (-) Delta 9 THC as an hypnotic. An experimental study of three dose levels. Psychopharmacologia 1973, 33:355-364.
39. Buysse D.J., Reynolds CFr, Monk T.H., Berman S.R., Kupfer D.J. The Pittsburgh sleep quality index: a new instrument for psychiatric practice and research. Psychiatry Res 1989, 28:198-213.
40. Narang S., Gibson D., Wasan A.D., Ross E.L., Michna E., Nedeljkovic S.S., et al. Efficacy of dronabinol as an adjuvant treatment for chronic pain patients on opioid therapy. JPain 2008, 9:254-264.
41. Portenoy R.K., Ganae-Motan E.D., Allende S., Yanagihara R., Shaiova L., Weinstein S., et al. Nabiximols for opioid-treated cancer patients with poorly-controlled chronic pain: a randomized, placebo-controlled, graded-dose trial. JPain 2012, 13:438-449.
42. Nurmikko T.J., Serpell M.G., Hoggart B., Toomey P.J., Morlion B.J., Haines D. Sativex successfully treats neuropathic pain characterised by allodynia: a randomised, double-blind, placebo-controlled clinical trial. Pain 2007, 133:210-220.
43. Ware M.A., Wang T., Shapiro S., Robinson A., Ducruet T., Huynh T., et al. Smoked cannabis for chronic neuropathic pain: a randomized controlled trial. Can Med Assoc J 2010, 182:e694-701.
44. Beaulieu P. Effects of nabilone, a synthetic cannabinoid, on postoperative pain. Can J Anaesth 2006, 53:769-775.
45. Berman J.S., Symonds C., Birch R. Efficacy of two cannabis based medicinal extracts for relief of central neuropathic pain from brachial plexus avulsion: results of a randomised controlled trial. Pain 2004, 112:299-306.
46. Bestard J.A., Toth C.C. An open-label comparison of nabilone and gabapentin as adjuvant therapy or monotherapy in the management of neuropathic pain in patients with peripheral neuropathy. Pain Pract 2011, 11:353-368.
47. Blake D.R., Robson P., Ho M., Jubb R.W., McCabe C.S. Preliminary assessment of the efficacy, tolerability and safety of a cannabis-based medicine (Sativex) in the treatment of pain caused by rheumatoid arthritis. Rheumatology 2006, 45:50-52.
48. Frank B., Serpell M., Hughes J., Matthews J., Kapur D. Comparison of analgesic effects and patient tolerability of nabilone and dihydrocodeine for chronic neuropathic pain: randomised, crossover, double blind study. Br Med J 2008, 336:199-201.
49. Haroutiunian S., Rosen G., Shouval R., Davidson E. Open-label, add-on study of tetrahydrocannabinol for chronic nonmalignant pain. JPain Palliat Care Pharmacother 2008, 22:213-217.
50. Notcutt W., Price M., Miller R., Newport S., Phillips C., Simmons S., et al. Initial experiences with medicinal extracts of cannabis for chronic pain: results from 34 'N of 1' studies. Anaesthesia 2004, 59:440-452.
51. Toth C., Mawani S., Brady S., Chan C., Liu C., Mehina E., et al. An enriched-enrolment, randomized withdrawal, flexible-dose, double-blind, placebo-controlled, parallel assignment efficacy study of nabilone as adjuvant in the treatment of diabetic peripheral neuropathic pain. Pain 2012, 153:2073-2082.
52. Collin C., Ehler E., Waberzinek G., Alsindi Z., Davies P., Powell K., et al. Adouble-blind, randomized, placebo-controlled, parallel-group study of Sativex, in subjects with symptoms of spasticity due to multiple sclerosis. Neurol Res 2010, 32:451-459.
53. Novotna A., Mares J., Ratcliffe S., Novakova I., Vachova M., Zapletalova O., et al. Arandomized, double-blind, placebo-controlled, parallel-group, enriched-design study of nabiximols* (Sativex), as add-on therapy, in subjects with refractory spasticity caused by multiple sclerosis. Eur J Neurol 2011, 18:1122-1131.
54. Rog D.J., Nurmikko T.J., Friede T., Young C.A. Randomized, controlled trial of cannabis based medicine in central pain in multiple sclerosis. Neurology 2005, 65:812-819.
55. Vaney C., Heinzel-Gutenbrunner M., Jobin P., Tschopp F., Gattlen B., Hagen U., et al. Efficacy, safety and tolerability of an orally administered cannabis extract in the treatment of spasticity in patients with multiple sclerosis: a randomized, double-blind, placebo-controlled, crossover study. Mult Scler 2004, 10:417-424.
56. Wade D.T., Makela P., Robson P., House H., Bateman C. Do cannabis-based medicinal extracts have general or specific effects on symptoms in multiple sclerosis? A double-blind, randomized, placebo-controlled study on 160 patients. Mult Scler 2004, 10:434-441.
57. Zajicek J.P., Hobart J.C., Slade A., Barnes D., Mattison P.G. MUltiple Sclerosis and Extract of Cannabis: results of the MUSEC trial. JNeurol Neurosurg Psychiatry 2012, 83:1125-1132.
58. Brady C.M., DasGupta R., Dalton C., Wiseman O.J., Berkley K.J., Fowler C.J. An open-label pilot study of cannabis-based extracts for bladder dysfunction in advanced multiple sclerosis. Mult Scler 2004, 10:425-433.
59. Zajicek J., Fox P., Sanders H., Wright D., Vickery J., Nunn A., et al. Cannabinoids for treatment of spasticity and other symptoms related to multiple sclerosis (CAMS study): multicentre randomised placebo-controlled trial. Lancet 2003, 362:1517-1526.
60. Zajicek J.P., Sanders H.P., Wright D.E., Vickery P.J., Ingram W.M., Reilly S.M., et al. Cannabinoids in multiple sclerosis (CAMS) study: safety and efficacy data for 12 months follow up. JNeurol Neurosurg Psychiatry 2005, 76:1664-1669.
61. Weber M., Goldman B., Truniger S. Tetrahydrocannabinol (THC) for cramps in amyotrophic lateral sclerosis: a randomised, double-blind crossover trial. JNeurol Neurosurg Psychiatry 2010, 81:1135-1140.
62. Gross H., Ebert M.H., Faden V.B. Adouble blind trial of 9-tetrahydrocannabinol in primary anorexia nervosa. JClin Psychopharmacol 1983, 3:165-171.
63. Johnson J.R., Burnell-Nugent M., Lossignol D., Ganae-Motan E.D., Potts R., Fallon M.T. Multicenter, double-blind, randomized, placebo-controlled, parallel-group study of the efficacy, safety, and tolerability of THC: CBD extract and THC extract in patients with intractable cancer-related pain. JPain Symptom Manage 2010, 39:167-179.
64. Bedi G., Foltin R.W., Gunderson E.W., Rabkin J., Hart C.L., Comer S.D., et al. Efficacy and tolerability of high-dose dronabinol maintenance in HIV-positive marijuana smokers: a controlled laboratory study. Psychopharmacology 2010, 212:675-686.
65. Haney M., Gunderson E.W., Rabkin J., Hart C.L., Vosburg S.K., Comer S.D., et al. Dronabinol and marijuana in HIV-positive marijuana smokers: caloric intake, mood, and sleep. JAcquir Immune Defic Syndr 2007, 45:545-554.
66. Fraser G.A. The use of a synthetic cannabinoid in the management of treatment-resistant nightmares in posttraumatic stress disorder (PTSD). CNS Neurosci Ther 2009, 15:84-88.
67. Ware M.A., Fitzcharles M.A., Joseph L., Shir Y. The effects of nabilone on sleep in fibromyalgia: results of a randomized controlled trial. Anesth Analg 2010, 110:604-610.
68. Wright S., Duncombe P., Altman D.G. Assessment of blinding to treatment allocation in studies of a cannabis-based medicine (Sativex(R)) in people with multiple sclerosis: a new approach. Trials 2012, 13:189.
69. Hays R.D., Martin S.A., Sesti A.M., Spritzer K.L. Psychometric properties of the medical outcomes study sleep measure. Sleep Med 2005, 6:41-44.
70. Parrott A.C., Hindmarch I. Factor analysis of a sleep evaluation questionnaire. Psychol Med 1978, 8:325-329.
71. Swift W., Wong A., Li K.M., Arnold J.C., McGregor I.S. Analysis of cannabis seizures in NSW, Australia: cannabis potency and cannabinoid profiled. PLoS One 2013, 8:e70052. 10.1371/journal.pone.0070052.